Xamoterol, sold under the brand names Corwin, Carwin, Corwil, and Xamtol among others, is a cardiac stimulant which is used in the treatment of heart failure.[1] It acts as a selective partial agonist of the β1-adrenergic receptor.[1] The drug has no β2-adrenergic receptor agonistic activity.[2] Xamoterol provides cardiac stimulation at rest but acts as a blocker during exercise.[3]
 | |
| Clinical data | |
|---|---|
| Trade names | Corwin, Carwin, Corwil, Xamtol |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H25N3O5 |
| Molar mass | 339.392 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Xamoterol is not available in the United States.[4][5] It is marketed in the United Kingdom, Austria, Belgium, and Luxembourg.[5]
References
edit- ^ a b Marlow HF (1989). "Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure". British Journal of Clinical Pharmacology. 28 (Suppl 1): 23S–30S. doi:10.1111/j.1365-2125.1989.tb03570.x. PMC 1379873. PMID 2572251.
- ^ "Xamoterol: Uses, Interactions, Mechanism of Action". DrugBank Online. 23 June 2017. Retrieved 23 July 2024.
- ^ Rang HP, Dale MM, Ritter JM, Moore PK (1999). Pharmacology (5th ed.). Edinburgh; New York: Churchill Livingstone. p. 163. ISBN 0443059748.
- ^ "Drugs@FDA: FDA-Approved Drugs". accessdata.fda.gov. Retrieved 23 July 2024.
- ^ a b Schweizerischer Apotheker-Verein (2000). Index Nominum 2000: International Drug Directory. Index nominum. Medpharm Scientific Publishers. p. 1099. ISBN 978-3-88763-075-1. Retrieved 23 July 2024.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |